MediPharm Labs - Interim CEO and Director, Keith Strachan.
Interim CEO and Director, Keith Strachan.
Source: New Green Frontier.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • MediPharm (LABS) has received a Canadian GMP pharmaceutical drug establishment license
  • The license, issued by Health Canada, is a first of its kind for cannabis manufacturing in North America
  • The company plans to leverage the license against mutual recognition agreements between Canada and other regulatory authorities
  • The license can be recognized in over 50 countries including the U.S.
  • MediPharm develops and manufactures cannabis concentrates, active pharmaceutical ingredients and advanced derivative products
  • MediPharm (LABS) is up by 1.09 per cent and is currently trading at $0.465 per share

MediPharm (LABS) has received a Canadian GMP pharmaceutical drug establishment license.

The license, issued by Health Canada, is a first of its kind for cannabis manufacturing in North America. It can be used to manufacture, test and sell active pharmaceutical ingredients and drug products containing cannabis.

MediPharm plans to leverage the license against mutual recognition agreements between Canada and other regulatory authorities, including Europe, Australia, the U.K. and Switzerland.

The company will use the license in conjunction with its Australian TGA GMP certification to optimize supply chains for the export of its products to over five countries in 2021.

As part of the International Pharmaceutical Inspection Co-operation Scheme, the Health Canada license can also be recognized in over 50 countries including the U.S.

MediPharm would be eligible for a U.S. FDA foreign inspection if a pharmaceutical customer files a registration application containing MediPharm API.

The company is now well-positioned to serve as a cannabis manufacturing partner across the global pharmaceutical landscape.

Keith Strachan, President and Interim CEO of MediPharm Labs, commented,

“MediPharm Labs now becomes one of a small number of companies who can take cannabis plant material and produce an API or a pharmaceutical drug product that could have marketing authorization by regulatory bodies such as the European Medicines Agency and FDA.”

MediPharm develops and manufactures cannabis concentrates, active pharmaceutical ingredients and advanced derivative products.

MediPharm (LABS) is up by 1.09 per cent and is currently trading at $0.465 per share as of 12:30 pm ET.

More From The Market Herald
High Tide - CEO, Raj Grover.

" High Tide’s (TSXV:HITI) Cabana Club loyalty program surpasses 500,000 members

High Tide’s (HITI) Cabana Club loyalty program has now amassed over 515,000 members.

" Potent Ventures Inc. (CSE:POT) partners with Dean’s Dairy and Specialty Foods for the Gummy Project

Potent Ventures (POT) has entered into a distribution partnership with Dean’s Dairy & Specialty Foods, to launch of the Gummy Project.
Ayr Wellness Inc. - Founder, Chairman & CEO, Jonathan Sandelman.

" Ayr Wellness’ (CSE:AYR.A) completes first sale from Phoenix facility and launches STiX products

Ayr Wellness (AYR.A) completed its first sale from its Phoenix, Arizona cultivation facility in tandem with the launch of its STiX Pre-Roll Co.